MDGL
NASDAQMadrigal Pharmaceuticals Inc.
Price$449.34-10.06 (-2.19%)
01:30 PM07:45 PM
News · 26 weeks56+33%
2026-04-192026-10-11
Mix2390d
- Other8(35%)
- Insider5(22%)
- SEC Filings4(17%)
- Analyst4(17%)
- Earnings1(4%)
- Leadership1(4%)
Latest news
25 items- PRMadrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)CONSHOHOCKEN, Pa., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on October 1, 2026 and October 14, 2026 to a total of 26 new non-executive employees as equity inducement awards under the terms of Madrigal’s 2025 Inducement Plan. The equity awards were approved by Madrigal’s independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4). The equity awards were granted as an inducement material to employees’ acceptance of employment with the company. The new emp
- PRMadrigal Announces Publication in the Journal of Hepatology Demonstrating Consistent Rezdiffra Efficacy Across Common MASH Genetic Risk VariantsSecondary analysis of the Phase 3 MAESTRO-NASH trial demonstrated Rezdiffra improved histology and MRI-PDFF across common genetic variants associated with MASH progression CONSHOHOCKEN, Pa., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced the publication of a pre-specified secondary analysis from the Phase 3 MAESTRO-NASH trial in the Journal of Hepatology evaluating whether common genetic risk variants associated with MASH altered patient response to Rezdiffra® (resmetirom). The analysis demonstrated that treatme
- ANALYSTGoldman resumed coverage on Madrigal Pharmaceuticals with a new price targetGoldman resumed coverage of Madrigal Pharmaceuticals with a rating of Buy and set a new price target of $704.00
- ANALYSTCitigroup initiated coverage on Madrigal Pharmaceuticals with a new price targetCitigroup initiated coverage of Madrigal Pharmaceuticals with a rating of Buy and set a new price target of $725.00
- PRMadrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)CONSHOHOCKEN, Pa., Sept. 16, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on September 1, 2026 and September 14, 2026 to a total of 27 new non-executive employees as equity inducement awards under the terms of Madrigal’s 2025 Inducement Plan. The equity awards were approved by Madrigal’s independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4). The equity awards were granted as an inducement material to employees’ acceptance of employment with the company. The ne
- INSIDERPresident and CEO Sibold William John sold $6,239,198 worth of shares (11,583 units at $538.65) as part of a pre-agreed trading plan, decreasing direct ownership by 6% to 197,746 units (SEC Form 4) (for tax liability)4 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Issuer)
- PRMadrigal Pharmaceuticals to Participate in the 2026 Cantor Global Healthcare ConferenceCONSHOHOCKEN, Pa., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today that the company will participate in the 2026 Cantor Global Healthcare Conference on Thursday, Sept. 10, 2026 at 1:00 P.M. EDT. The presentation will be webcast live and may be accessed here or by visiting Madrigal’s Investor Relations Events and Presentations page. A replay of the webcast will be available after the event. About Madrigal PharmaceuticalsMadrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. M
- INSIDERGeneral Counsel Kelley Shannon T sold $341,940 worth of shares (664 units at $514.97), decreasing direct ownership by 5% to 11,474 units (SEC Form 4) to cover taxes4 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Issuer)
- PRMadrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)CONSHOHOCKEN, Pa., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on August 15, 2026 to 13 new non-executive employees as equity inducement awards under the terms of Madrigal’s 2025 Inducement Plan. The equity awards were approved by Madrigal’s independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4). The equity awards were granted as an inducement material to employees’ acceptance of employment with the company. The new employees received, in the aggregat
- INSIDERDirector Reed John C was granted 647 shares (SEC Form 4)4 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Issuer)
- INSIDERSEC Form 3 filed by new insider Reed John C3 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Issuer)
- SECMadrigal Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Filer)
- PRMadrigal Appoints John C. Reed, M.D., Ph.D., to its Board of DirectorsCONSHOHOCKEN, Pa., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced it has appointed John C. Reed, M.D., Ph.D., to its Board of Directors. Dr. Reed currently serves as Executive Vice President, Innovative Medicine, Research & Development at Johnson & Johnson ("J&J") and is a member of J&J’s Executive Committee, where he leads research and development across oncology, immunology, neuroscience and other areas of significant unmet medical need. Julian Baker, Chairman of the Board of Directors of Madrigal, stated, "I
- PRMadrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)CONSHOHOCKEN, Pa., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on August 1, 2026 to ten new non-executive employees as equity inducement awards under the terms of Madrigal’s 2025 Inducement Plan. The equity awards were approved by Madrigal’s independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4). The equity awards were granted as an inducement material to employees’ acceptance of employment with the company. The new employees received, in the aggregat
- PRMadrigal Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth ConferenceCONSHOHOCKEN, Pa., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today that the company will participate in the Canaccord Genuity 46th Annual Growth Conference on Tuesday, Aug. 11, 2026 at 12:00 P.M. EDT. The presentation will be webcast live and may be accessed here or by visiting Madrigal’s Investor Relations Events and Presentations page. A replay of the webcast will be available after the event. About Madrigal PharmaceuticalsMadrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical ne
- ANALYSTMadrigal Pharmaceuticals upgraded by Wolfe Research with a new price targetWolfe Research upgraded Madrigal Pharmaceuticals from Peer Perform to Outperform and set a new price target of $605.00
- SECSEC Form 10-Q filed by Madrigal Pharmaceuticals Inc.10-Q - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Filer)
- SECSEC Form 8-K filed by Madrigal Pharmaceuticals Inc.8-K - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Filer)
- PRMadrigal Pharmaceuticals Reports Second-Quarter 2026 Financial Results and Provides Corporate UpdatesSecond-quarter 2026 Rezdiffra® (resmetirom) net sales of $364.3 million, representing year-over-year growth of 71% As of June 30, 2026, more than 49,000 patients on Rezdiffra, more than doubling from 2Q25 reflecting continued strong physician adoption and high patient demandStrengthened IP portfolio with 3 new resmetirom patents, including F4c patent MGL-2086 (oral GLP-1) Phase 1 trial dosing initiated in June 2026 as part of Rezdiffra/MGL-2086 combination program in MASHReports cash, cash equivalents, restricted cash and marketable securities of $838.9 million as of June 30, 2026 Company to host conference call today, July 30, 2026, at 8 a.m. EDT CONSHOHOCKEN, Pa., July 30, 2026 (GLOBE N
- ANALYSTWells Fargo initiated coverage on Madrigal Pharmaceuticals with a new price targetWells Fargo initiated coverage of Madrigal Pharmaceuticals with a rating of Overweight and set a new price target of $685.00
- PRMadrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)CONSHOHOCKEN, Pa., July 21, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on July 15, 2026 to ten new non-executive employees as equity inducement awards under the terms of Madrigal’s 2025 Inducement Plan. The equity awards were approved by Madrigal’s independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4). The equity awards were granted as an inducement material to employees’ acceptance of employment with the company. The new employees received, in the aggregate
- INSIDERPresident and CEO Sibold William John converted options into 50,000 shares and sold $1,368,253 worth of shares (2,500 units at $547.30), increasing direct ownership by 29% to 209,329 units (SEC Form 4) to cover taxes4 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Issuer)
- SECSEC Form 144 filed by Madrigal Pharmaceuticals Inc.144 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Subject)
- PRMadrigal Pharmaceuticals to Release Second-Quarter 2026 Financial Results and Host Webcast on July 30, 2026CONSHOHOCKEN, Pa., July 16, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today that it will release its second-quarter 2026 financial results on Thursday, July 30, 2026, prior to the open of the U.S. financial markets. Following the announcement, Madrigal’s management will host a live webcast at 8 a.m. Eastern Time to review the Company’s financial and operating results. The live webcast may be accessed at the Investor Relations section of the Madrigal Pharmaceuticals website. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. The webcast will be available approximately two ho
- PRMadrigal Pharmaceuticals Announces Three New Resmetirom Patents, Strengthening IP PortfolioReceived two new U.S. Rezdiffra® (resmetirom) patents in F2/F3; both patents will be listed in the FDA’s Orange Book Received new U.S. resmetirom patent directed to a method of administering resmetirom to treat well-compensated cirrhosis (F4c) CONSHOHOCKEN, Pa., July 13, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that the United States Patent and Trademark Office (USPTO) issued three new resmetirom patents. Bill Sibold, Chief Executive Officer of Madrigal, stated: "Building a robust patent estate is a core pillar of
MDGL FAQ
7 questionsWhat does Madrigal Pharmaceuticals Inc. do?
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is MGL-3196, a liver-directed selective thyroid hormone receptor-Ã agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.Where does MDGL stock trade?
Madrigal Pharmaceuticals Inc. (MDGL) is listed on NASDAQ.What sector and industry is MDGL in?
Madrigal Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Madrigal Pharmaceuticals Inc. go public?
Madrigal Pharmaceuticals Inc. (MDGL) completed its IPO in 2007.What are analysts saying about MDGL?
Madrigal Pharmaceuticals Inc. has had 8 recent analyst actions on file. The most recent action was from Goldman: Buy on 2026-09-24.What companies are similar to MDGL?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare MDGL side-by-side with any of them on Quantisnow.How can I track MDGL on Quantisnow?
Quantisnow aggregates Madrigal Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow MDGL to receive live email and push alerts on every new disclosure.